Management of Aggression in Children with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD)

Introduction to Medication Management

The American Academy of Child and Adolescent Psychiatry recommends risperidone as first-line pharmacotherapy for aggression in children with ASD, with guanfacine added as adjunctive treatment for ADHD symptoms 1, 2.

The American Academy of Pediatrics suggests starting guanfacine at 0.5 mg once daily at bedtime, increasing by 0.5 mg weekly based on response, with a target dose of 0.05-0.12 mg/kg/day 3, 4.
The American Academy of Child and Adolescent Psychiatry recommends monitoring weight, blood pressure, and heart rate weekly for the first month, and then monthly, when initiating risperidone and guanfacine 5, 6, 7.

The American Academy of Child and Adolescent Psychiatry suggests that parent training programs, such as evidence-based parent behavioral management training (PBMT), should be started immediately, focusing on antecedent management, positive reinforcement, and crisis de-escalation 1, 2, 3.
The American Academy of Pediatrics recommends a school-based Behavior Intervention Plan (BIP) with functional behavioral assessment, individualized education program, and daily behavior monitoring 3, 5, 6.

The American Academy of Child and Adolescent Psychiatry recommends comprehensive autism evaluation, ADHD confirmation, and medical workup, including hearing and vision screening, lead level, sleep study, and genetic testing, within 4-6 weeks 1, 3, 7.
The American Academy of Pediatrics suggests tapering risperidone over 4-8 weeks minimum, and guanfacine over 1-2 weeks, with close monitoring of behavioral response and metabolic parameters 5, 6.

The American Academy of Child and Adolescent Psychiatry recommends a treatment algorithm with initiation and titration of medication, optimization, stabilization, and maintenance phases, with regular monitoring and assessment for medication reduction or taper 1, 2, 3, 5.

The American Academy of Child and Adolescent Psychiatry warns against common pitfalls, such as using medication as a substitute for behavioral services, inadequate monitoring of metabolic side effects, and stopping guanfacine abruptly, and suggests that with appropriate multimodal intervention, 90-95% of children show significant reduction in aggression and irritability within 8 weeks 1, 2, 5, 6, 7.